TABLE 3.
Crohn disease patients: Remission
| Patient | Interval between studies, weeks | Treatment | CDAI |
GLP-2 levels, pmol/L
|
Sugar absorption, %
|
Ratio | |||
|---|---|---|---|---|---|---|---|---|---|
| Fasting | Postprandial | 3-OMG | Lactulose | Mannitol | |||||
| 1 | 8 | Steroids→Aza | 80 | 14 | 28 | 74.0 | 1.0 | 42.6 | 0.024 |
| 2 | 8 | Steroids→Aza | 110 | 27 | 40 | 76.2 | 1.2 | 45.1 | 0.031 |
| 3 | 12 | Steroids→Aza | 60 | 17 | 33 | 63.9 | 1.3 | 29.6 | 0.046 |
| 4 | 10 | Steroids→Aza | 120 | 22 | 36 | 57.3 | 1.4 | 27.3 | 0.045 |
| 5 | 12 | Steroids→Aza | 80 | 18 | 41 | 62.7 | 0.85 | 28.2 | 0.033 |
| 6 | 10 | Steroids | 80 | 13 | 34 | 46.0 | 0.7 | 31.9 | 0.021 |
| 7 | 8 | Steroids→Aza | 120 | 53 | 60 | 44.1 | 1.1 | 43.9 | 0.026 |
| Mean ± SD | 93±24 | 23.9±14 | 38.9±10.3 | 60.6±12.5 | 1.08±0.25 | 35.5±8 | 0.032±0.010 | ||
Glucagon-like peptide 2 (GLP-2) levels determined by radioimmuno assay using a specific antibody for intact GLP-2 (amino acid residues 1 to 33) (20). Sugar probe absorption is reported as the proportion of orally administered probe recovered in urine after an overnight collection, quantified using high-performance liquid chromatography (23,34). 3-OMG 3-O-methyl glucose; AZA Azathioprine; CDAI Crohn disease activity index